Drug intelligence / Profile preview

PF-07934040 + cetuximab

Development stage: Unknown
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

PF-07934040 + cetuximab is a combination therapy being studied for advanced solid tumors harboring mutations in the KRAS gene, specifically metastatic colorectal cancer (mCRC)[3]. PF-07934040 is an oral small molecule inhibitor targeting KRAS, a GTPase protein frequently mutated in cancer and responsible for abnormal cellular growth signaling[5]. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This combination is under evaluation to assess safety, tolerability, and preliminary anti-tumor activity in patients with KRAS-mutant mCRC[3]. The developer is Pfizer, and the therapy is currently in Phase 1 clinical trials as a combination[3].

Other names: PF-4040PF4040PF 4040

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on PF-07934040 + cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07934040 + cetuximab.

Explore the full profile